OGT and colorectal cancer: We confirmed this result by inhibiting OGT and/or EZH2: respectively with Ac5S-GlcNAc (Ac5S) and GSK343 specific inhibitors (Figure 4E) and validated them also in LS174T human colorectal cancer cell line (Supplementary Figure S2).